Close this search box.
Day: December 6, 2022

TrueBinding Highlights the Potential of TB006’s Unique Mechanism of Action as a Novel Approach for the Treatment of Alzheimer’s Disease at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Novel antibody, TB006, demonstrated improvements in cognition and function and was well tolerated in a one-month Phase 1b/2 trial in mild to severe Alzheimer’s disease (AD) patients TB006 also demonstrated improvements in PET and MR imaging, consistent with dissolution of

Read More

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing

Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing The Series C extension round will accelerate clinical development, manufacturing scale-up and pre-commercialization activities of Pulmocide’s lead product candidate, opelconazole Paris, France, December 6th 2022 – Jeito Capital (“Jeito”), the largest fully independent international private equity firm dedicated to healthcare and biopharma, announced

Read More